Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the
appointment of Ali Hariri, M.D., as its Chief Medical Officer,
overseeing clinical development efforts for the company’s promising
pipeline of therapies to treat rare diseases. Dr. Hariri will
report to Vijay Modur, M.B.B.S., Ph.D., the company’s Head of
Research and Development.
Dr. Hariri was previously Senior Global Project Head in Rare
Disease Clinical Development at Sanofi where he oversaw key
functions responsible for advancing a number of investigational
therapies along with full approval for on-market therapies within
the Sanofi Genzyme specialty care business. Prior to his role as
Global Project Head at Sanofi Genzyme, Dr. Hariri held several
positions of increasing responsibility with expertise across a
range of therapeutic areas including nephrology and immunology.
Before joining Sanofi, Dr. Hariri held clinical development roles
at Ionis Pharmaceuticals and Takeda and was a practicing
nephrologist.
“Our top priority at Eloxx remains the advancement of ELX-02,
which is currently in Phase 2 clinical trials. Dr. Hariri’s
experience in rare disease clinical development brings the type of
skills necessary to advance this key imperative while quickly
advancing our promising pre-clinical pipeline into human trials,”
said Sumit Aggarwal, President and CEO of Eloxx.
The company reaffirmed its expectation that data from the first
four treatment arms of the ELX-02 Phase 2 study will be available
in the fourth quarter of 2021. ELX-02 is currently in Phase 2
clinical trials in CF patients affected by nonsense mutations in
the CFTR (CF transmembrane conductance regulator) gene. The Phase 2
trials are designed to evaluate the safety of ELX-02 and assess its
biological activity.
“The Eloxx pipeline has tremendous potential, and I’m thrilled
to be joining a team with the skills and commitment to advance
meaningful therapies on behalf of patients,” said Dr. Hariri.
Dr. Hariri earned his M.D. from the University of California San
Diego School of Medicine, completed his residency at Case Western
Reserve, and did his fellowship in nephrology at Yale University
School of Medicine.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is engaged in the science of
ribosome modulation, leveraging both its innovative TURBO-ZM™
chemistry technology platform in an effort to develop novel
Ribosome Modulating Agents (RMAs) and its library of Eukaryotic
Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational
product candidate, ELX-02, is a small molecule drug candidate
designed to restore production of full-length functional proteins.
ELX-02 is in clinical development focusing on cystic fibrosis.
ELX-02 is an investigational drug that has not been approved by any
global regulatory body. Eloxx also has preclinical programs focused
on select rare diseases including inherited diseases, cancer caused
by nonsense mutations, kidney diseases, including autosomal
dominant polycystic kidney disease, as well as rare ocular genetic
disorders.
For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of present and
historical facts contained in this press release, including without
limitation, statements regarding the expected timing of trials and
results from clinical studies of our product candidate, the
expansion of our clinical trial sites and the potential of our
product candidate to treat nonsense mutations are forward-looking
statements. Forward-looking statements can be identified by the
words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential,”
“seeks,” or “continue” or the negative of these terms similar
expressions, although not all forward-looking statements contain
these words.
Forward-looking statements are based on management's current
plans, estimates, assumptions and projections based on information
currently available to us. Forward-looking statements are subject
to known and unknown risks, uncertainties and assumptions, and
actual results or outcomes may differ materially from those
expressed or implied in the forward-looking statements due to
various important factors, including, but not limited to: our
ability to progress any product candidates in preclinical or
clinical trials; the uncertainty of clinical trial results and the
fact that positive results from preclinical studies are not always
indicative of positive clinical results; the scope, rate and
progress of our preclinical studies and clinical trials and other
research and development activities; the competition for patient
enrollment from drug candidates in development; the impact of the
global COVID-19 pandemic on our clinical trials, operations,
vendors, suppliers, and employees; our ability to obtain the
capital necessary to fund our operations; the cost of filing,
prosecuting, defending and enforcing any patent claims and other
intellectual property rights; our ability to obtain financial in
the future through product licensing, public or private equity or
debt financing or otherwise; general business conditions,
regulatory environment, competition and market for our products;
and business ability and judgment of personnel, and the
availability of qualified personnel and other important factors
discussed under the caption “Risk Factors” in our Quarterly Report
on Form 10-Q for the quarterly period ended June 30, 2021, as any
such factors may be updated from time to time in our other filings
with the SEC, accessible on the SEC’s website at www.sec.gov and
the “Financials & Filings” page of our website at
https://investors.eloxxpharma.com/financial-information/sec-filings
All forward-looking statements speak only as of the date of this
press release and, except as required by applicable law, we have no
obligation to update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact
InvestorsJohn
Woolfordjohn.woolford@westwicke.com443.213.0506
MediaLaureen Cassidylaureen@outcomescg.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024